Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Consistent data coming from biochemical studies have evidenced a brain-derived neurotrophic factor (BDNF) serum reduction in depressed patients compared to controls and a restoration following antidepressant treatment. However, to date, no study has evaluated whether BDNF synthesis in leukocytes could contribute to such modulation. Therefore, in this study, we analysed BDNF mRNA levels in leukocytes from 21 depressed patients prior to and during escitalopram treatment and from 23 control subjects showing that BDNF mRNA levels were decreased in drug-free depressed patients and that 12 wk escitalopram treatment was able to reverse this deficit. Interestingly, changes in BDNF mRNA levels paralleled BDNF serum increase during antidepressant treatment, and were correlated with symptoms improvement. Our results indicate that BDNF serum modulation observed in depressed patients is associated with BDNF synthesis alteration in leukocytes and suggest that these peripheral cells might play an active role in the mechanisms of action of antidepressants.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalInternational Journal of Neuropsychopharmacology
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Brain-Derived Neurotrophic Factor
Antidepressive Agents
Messenger RNA
Citalopram
Leukocytes
Therapeutics
Serum
Pharmaceutical Preparations

Keywords

  • BDNF
  • Escitalopram
  • Leukocytes
  • Major depression
  • Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health

Cite this

@article{0776a5b9de3d4ddb94ee2300639ea73f,
title = "Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment",
abstract = "Consistent data coming from biochemical studies have evidenced a brain-derived neurotrophic factor (BDNF) serum reduction in depressed patients compared to controls and a restoration following antidepressant treatment. However, to date, no study has evaluated whether BDNF synthesis in leukocytes could contribute to such modulation. Therefore, in this study, we analysed BDNF mRNA levels in leukocytes from 21 depressed patients prior to and during escitalopram treatment and from 23 control subjects showing that BDNF mRNA levels were decreased in drug-free depressed patients and that 12 wk escitalopram treatment was able to reverse this deficit. Interestingly, changes in BDNF mRNA levels paralleled BDNF serum increase during antidepressant treatment, and were correlated with symptoms improvement. Our results indicate that BDNF serum modulation observed in depressed patients is associated with BDNF synthesis alteration in leukocytes and suggest that these peripheral cells might play an active role in the mechanisms of action of antidepressants.",
keywords = "BDNF, Escitalopram, Leukocytes, Major depression, Serum",
author = "Annamaria Cattaneo and Luisella Bocchio-Chiavetto and Roberta Zanardini and Elena Milanesi and Anna Placentino and Massimo Gennarelli",
year = "2010",
month = "2",
doi = "10.1017/S1461145709990812",
language = "English",
volume = "13",
pages = "103--108",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "1",

}

TY - JOUR

T1 - Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment

AU - Cattaneo, Annamaria

AU - Bocchio-Chiavetto, Luisella

AU - Zanardini, Roberta

AU - Milanesi, Elena

AU - Placentino, Anna

AU - Gennarelli, Massimo

PY - 2010/2

Y1 - 2010/2

N2 - Consistent data coming from biochemical studies have evidenced a brain-derived neurotrophic factor (BDNF) serum reduction in depressed patients compared to controls and a restoration following antidepressant treatment. However, to date, no study has evaluated whether BDNF synthesis in leukocytes could contribute to such modulation. Therefore, in this study, we analysed BDNF mRNA levels in leukocytes from 21 depressed patients prior to and during escitalopram treatment and from 23 control subjects showing that BDNF mRNA levels were decreased in drug-free depressed patients and that 12 wk escitalopram treatment was able to reverse this deficit. Interestingly, changes in BDNF mRNA levels paralleled BDNF serum increase during antidepressant treatment, and were correlated with symptoms improvement. Our results indicate that BDNF serum modulation observed in depressed patients is associated with BDNF synthesis alteration in leukocytes and suggest that these peripheral cells might play an active role in the mechanisms of action of antidepressants.

AB - Consistent data coming from biochemical studies have evidenced a brain-derived neurotrophic factor (BDNF) serum reduction in depressed patients compared to controls and a restoration following antidepressant treatment. However, to date, no study has evaluated whether BDNF synthesis in leukocytes could contribute to such modulation. Therefore, in this study, we analysed BDNF mRNA levels in leukocytes from 21 depressed patients prior to and during escitalopram treatment and from 23 control subjects showing that BDNF mRNA levels were decreased in drug-free depressed patients and that 12 wk escitalopram treatment was able to reverse this deficit. Interestingly, changes in BDNF mRNA levels paralleled BDNF serum increase during antidepressant treatment, and were correlated with symptoms improvement. Our results indicate that BDNF serum modulation observed in depressed patients is associated with BDNF synthesis alteration in leukocytes and suggest that these peripheral cells might play an active role in the mechanisms of action of antidepressants.

KW - BDNF

KW - Escitalopram

KW - Leukocytes

KW - Major depression

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=77949658730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949658730&partnerID=8YFLogxK

U2 - 10.1017/S1461145709990812

DO - 10.1017/S1461145709990812

M3 - Article

C2 - 19835669

AN - SCOPUS:77949658730

VL - 13

SP - 103

EP - 108

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 1

ER -